

VISION ACADEMY VIEWPOINT

The Vision Academy is a partnership between Bayer and ophthalmic specialists, established with the aim of addressing key clinical challenges in the field of retinal diseases: www.visionacademy.org.

The Role of OCT-A in Retinal Disease Management

Background

In recent years there has been rapid development in both the technology and number of imaging modalities utilized in the field of ophthalmology; in particular, optical coherence tomography (OCT) has become a widely used imaging tool. Optical coherence tomography angiography (OCT-A) is a non-invasive, non-dye-based imaging technique that can rapidly produce high-resolution, cross-sectional scans of vascular flow in seconds.¹⁻⁴

As such, there is growing interest in the use of this technique in the retinal disease community. However, to date, no clinical trials have included OCT-A-based endpoints. There is therefore little consensus on the role of OCT-A in the diagnosis or monitoring of retinal disease and current recommendations state that the use of OCT-A is not essential for good patient management.⁵

This Viewpoint examines the role of OCT-A in the management of neovascular age-related macular degeneration (nAMD), with a focus on its current utility, limitations, and potential for future applications, both clinically and from a research perspective.⁵

Endorsed by the Vision Academy
in May 2019.

Date of review: October 2025



Full consensus



Variations in opinion

Viewpoint

- 1. At this time, OCT-A should be considered a complementary diagnostic tool in the portfolio of imaging modalities with fluorescein angiography, indocyanine green angiography, and structural OCT**



The effectiveness of OCT-A has been demonstrated in principle for the diagnosis of choroidal neovascularization in patients with nAMD, and the technique has the potential to improve the accuracy of diagnosis in clinical practice.⁶ OCT-A in combination with structural OCT has been shown to be more effective than either fluorescein angiography or OCT-A alone for the evaluation of macular complications associated with retinal disease.⁷ OCT-A may also be useful in cases where patients are unsuitable for dye-based techniques (e.g. allergy or pregnancy) or where accurate assessment may be difficult.² However, there are several challenges with the technique that should be considered:

- OCT-A has a limited ability to detect slowly flowing structures² and is also limited in its ability to detect the extent of vascular leakage
- Physician experience with OCT-A image interpretation is currently limited and there remains a lack of understanding of what constitutes normal and disease morphology, particularly for structures such as choriocapillaris

- 2. Physicians should be aware of the multiple imaging artifacts that are possible with OCT-A**



OCT-A image artifacts can be caused by distortions resulting from errors in image processing and display or ocular motion.⁸ Eye characteristics such as high myopia can also cause image artifacts.⁸ Furthermore, shadow artifacts can be caused by prominent media and vitreous opacities (“floaters”) and superficial retinal vessels.^{8,9} Interference from superficial vessels can also cause projection artifacts, even when using the latest software that may provide a partial solution to correct such segmentation errors.

References

1. Rabiolo A, Carnevali A, Bandello F *et al.* Optical coherence tomography angiography: evolution or revolution? *Expert Rev Ophthalmol* 2016; 11 (4): 243–245.
2. de Carlo TE, Romano A, Waheed NK *et al.* A review of optical coherence tomography angiography (OCTA). *Int J Retina Vitreous* 2015; 1: 5.
3. Cheng Y, Guo L, Pan C *et al.* Statistical analysis of motion contrast in optical coherence tomography angiography. *J Biomed Opt* 2015; 20 (11): 116004.
4. Jia Y, Bailey ST, Hwang TS *et al.* Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye. *Proc Natl Acad Sci U S A* 2015; 112 (18): E2395–2402.
5. Rodríguez FJ, Staurengi G and Gale R. The role of OCT-A in retinal disease management. *Graefes Arch Clin Exp Ophthalmol* 2018; 256 (11): 2019–2026.
6. Shaimov TB, Panova IE, Shaimov RB *et al.* Optical coherence tomography angiography in the diagnosis of neovascular age-related macular degeneration. *Vestn Oftalmol* 2015; 131 (5): 4–13.
7. Inoue M, Jung JJ, Balaratnasingam C *et al.* A comparison between optical coherence tomography angiography and fluorescein angiography for the imaging of type 1 neovascularization. *Invest Ophthalmol Vis Sci* 2016; 57 (9): OCT314–323.
8. Spaide RF, Fujimoto JG and Waheed NK. Image artifacts in optical coherence tomography angiography. *Retina* 2015; 35 (11): 2163–2180.
9. Chalam KV and Sambhav K. Optical coherence tomography angiography in retinal diseases. *J Ophthalmic Vis Res* 2016; 11 (1): 84–92.
10. Zhang A, Zhang Q, Chen CL *et al.* Methods and algorithms for optical coherence tomography-based angiography: a review and comparison. *J Biomed Opt* 2015; 20 (10): 100901.
11. Turgut B. Optical coherence tomography angiography – a general view. *European Ophthalmic Review* 2016; 10 (1): 39–42.
12. Jia Y, Tan O, Tokayer J *et al.* Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. *Opt Express* 2012; 20 (4): 4710–4725.
13. Schwartz DM, Fingler J, Kim DY *et al.* Phase-variance optical coherence tomography: a technique for noninvasive angiography. *Ophthalmology* 2014; 121 (1): 180–187.
14. Nam AS, Chico-Calero I and Vakoc BJ. Complex differential variance algorithm for optical coherence tomography angiography. *Biomed Opt Express* 2014; 5 (11): 3822–3832.
15. Phadikar P, Saxena S, Ruia S *et al.* The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. *Int J Retina Vitreous* 2017; 3: 1.
16. Charafeddin W, Nittala MG, Oregon A *et al.* Relationship between subretinal hyperreflective material reflectivity and volume in patients with neovascular age-related macular degeneration following anti-vascular endothelial growth factor treatment. *Ophthalmic Surg Lasers Imaging Retina* 2015; 46 (5): 523–530.

Further considerations

While OCT-A has shown great potential for use in clinical practice as an additional tool for diagnosis, its use as a primary method in diagnosis and disease monitoring is yet to be understood. There is currently no consensus on whether OCT-A would be useful in all cases or in specific patient subgroups.



The use of OCT-A is growing faster than the community's understanding of and experience with the technique, and there are a number of knowledge gaps the Vision Academy believes need to be addressed:

- Several methods of OCT-A image acquisition have been developed, using a variety of technical protocols that have not yet been sufficiently validated^{4,10-14}
- OCT-A may potentially identify new biomarkers for different retinal diseases, which may provide a valuable tool for detecting the early stages and progression of ocular diseases¹⁵; these could be used to monitor specific pathologies (e.g. subretinal hyperreflective material lesions) that may be helpful in monitoring disease activity and response to treatment.¹⁶ This, however, remains to be demonstrated
- The need for standard protocols for image acquisition and interpretation should be a primary focus. As a new technology, further research is needed to define best practice for OCT-A in various retinal diseases



Full consensus



Variations in opinion